Answers are grounded in this paper and cite their sources.
We found that below the CLSI breakpoint, there was no association between MIC and clinical outcome in paediatric shigellosis infections. However, S. flexneri patients had worse clinical outcomes when treated with gatifloxacin in this study regardless of MIC. Additionally, Shigella harbouring the qnrS gene are able to replicate efficiently in high concentrations of ciprofloxacin and we hypothesize that such strains possess a competitive advantage against fluoroquinolone-susceptible strains due to enhanced shedding and transmission.
No takes yet. Share an insight, caveat, or question.
Thompson et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: